<DOC>
	<DOCNO>NCT02097472</DOCNO>
	<brief_summary>The purpose study assess safety tolerability PATH-wSP , administer intramuscularly healthy Kenyan adult toddler prim pneumococcal conjugate vaccine ( PCV ) . Additionally , study explore whether measurable immune response elicit PATH-wSP administer healthy Kenyan adult toddler prim PCV .</brief_summary>
	<brief_title>Dose-Finding Study S.Pneumoniae Whole Cell Vaccine Adsorbed Alum ( PATH-wSP ) Healthy Kenyan Adults Toddlers</brief_title>
	<detailed_description />
	<mesh_term>Pneumonia</mesh_term>
	<mesh_term>Pneumonia , Pneumococcal</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Healthy young Kenyan adult 18 45 year age Willing provide write informed consent , able understand comply study requirements/procedures . Adult female subject surgically sterilize negative serum pregnancy test enrollment prior vaccination . Adult female must willing avoid become pregnant duration study , must agree employ effective form birth control duration study . Subjects willing avoid consumption herbal medication ( include herbal medication take mother , may transmit toddler breast milk ) could effect liver function bleed index course study . Healthy toddlers 12 15 month age complete primary EPI vaccine . Toddler 's parent willing provide write informed consent subject , able understand comply study requirement procedure . Not premature , birth weight &gt; 2.5 kg , weighttoheight Z score ≥ 2 time enrollment . Use investigational nonregistered drug within 90 day prior course study participation . History administration vaccine within 30 day prior administration study vaccine plan vaccination course study . History anaphylactic shock . Positive test malaria ( blood film ) time screen retested Visit 1 . Immunosuppression immunodeficiency , inclusive human immunodeficiency virus , medical history test screening . Chronic , clinically significant pulmonary , cardiovascular , hepatobiliary , gastrointestinal , renal , neurological , hematological functional abnormality major congenital defect illness require medical therapy , deem medical history clinical assessment . Evidence active hepatitis infection ( B C ) immunologic test screening . Any medical social condition opinion investigator interfere study objective pose risk study subject may prevent subject complete study followup . An employee ( first degree relative employee ) Sponsor , Clinical Research Organization , investigator site personnel . Any screening laboratory test result vital sign measurement outside normal parameter deem clinician clinically significant , include positive test malaria . Acute illness ( moderate severe ) and/or fever ( tympanic temperature &gt; 38°C adult &gt; 37.5°C toddler ) , acute limited illness require medical treatment , include use antibiotic treatment parasite . History allergic disease history serious reaction prior vaccination know hypersensitivity component study vaccine . Disorders require chronic administration immunemodifying drug within past 6 month prior administration study vaccine . Administration immunoglobulins and/or blood product within 6 month precede enrollment study ; anticipation administration study period . Known disturbance coagulation blood disorder adult subject self/first degree relative toddler subject ; receipt anticoagulant past 3 week . History meningitis seizures neurological disorder major psychiatric disorder ( adult ) . Female subject pregnant breastfeeding . Suspicion recent history alcohol substance abuse . Toddlers evidence congenital abnormality developmental delay . Toddlers evidence fetal alcohol syndrome history alcohol abuse mother pregnancy . Toddlers expose HIV , bear HIV infect mother , HIV positive either antibody polymerase chain reaction test .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2015</verification_date>
</DOC>